drugset / Trial / NCT07176286
18F-mFBG Cardiac Uptake With Lewy Body Dementia
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2026-10-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | M-FLUOROBENZYLGUANIDINE | Diagnostic / imaging agent | 222 mbq | Intravenous |
| Comparator | M-FLUOROBENZYLGUANIDINE | Diagnostic / imaging agent | 370 mbq | Intravenous |